Letters sent to healthcare professionals in June 2017

Letters were sent about Arsenic Trioxide (Trisenox), Uptravi▼ (selexipag), DepoCyte (cytarabine), Cinryze▼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).

• From: Medicines and Healthcare products Regulatory Agency
• Published: 20 July 2017

• Therapeutic area: Cancer, Cardiovascular disease and lipidology, Haematology, Immunology and vaccination and Infectious disease
  Show 3 more
  Paediatrics and neonatology, Respiratory disease and allergy, and Urology and nephrology

In June 2017, the following letters were sent to relevant healthcare professionals:

• Arsenic Trioxide (Trisenox) 1 mg/mL concentrate for solution for infusion: importation and over-labelling of United States (US) Trisenox stock as Teva UK interim supply

• Uptravi▼ (selexipag): concomitant use with strong CYP2C8 inhibitors (eg, gemfibrozil) now contraindicated

• Cinryze▼ (C1 esterase inhibitor [human]): recommendations to prescribers in view of a potential supply shortage

• DepoCyte (cytarabine): follow-up on EU supply issue

• Clexane (enoxaparin sodium): updates to strength expression, dose regimens in DVT/PE, use in patients with severe renal impairment

Article citation: Drug Safety Update volume 10 issue 12, July 2017: 4.

Published 20 July 2017